Mark Foletta Sells 2,000 Shares of DexCom (NASDAQ:DXCM) Stock

DexCom, Inc. (NASDAQ:DXCM) Director Mark Foletta sold 2,000 shares of the company’s stock in a transaction dated Friday, July 31st. The shares were sold at an average price of $80.00, for a total transaction of $160,000.00. Following the sale, the director directly owned 50,852 shares of the company’s stock, valued at $4,068,160. The trade was a 3.78% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

DexCom Stock Performance

Shares of NASDAQ:DXCM traded down $0.37 during trading on Tuesday, hitting $86.94. The company’s stock had a trading volume of 5,993,713 shares, compared to its average volume of 5,297,699. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.73 and a quick ratio of 1.43. The firm has a market cap of $32.81 billion, a price-to-earnings ratio of 34.36, a P/E/G ratio of 1.36 and a beta of 1.41. The company has a 50-day moving average of $73.44 and a 200-day moving average of $69.31. DexCom, Inc. has a 12 month low of $54.11 and a 12 month high of $87.85.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, July 30th. The medical device company reported $0.70 EPS for the quarter, beating analysts’ consensus estimates of $0.61 by $0.09. DexCom had a net margin of 20.12% and a return on equity of 35.94%. The business had revenue of $1.31 billion during the quarter, compared to analysts’ expectations of $1.29 billion. During the same period in the prior year, the company earned $0.48 earnings per share. The firm’s revenue was up 13.1% on a year-over-year basis. On average, sell-side analysts expect that DexCom, Inc. will post 2.6 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in DXCM. BOKF NA lifted its stake in shares of DexCom by 175.7% in the 4th quarter. BOKF NA now owns 35,314 shares of the medical device company’s stock valued at $2,344,000 after acquiring an additional 22,505 shares during the last quarter. Stephens Investment Management Group LLC grew its position in DexCom by 21.1% during the 4th quarter. Stephens Investment Management Group LLC now owns 1,042,801 shares of the medical device company’s stock worth $69,211,000 after acquiring an additional 181,701 shares during the last quarter. Eurizon Capital SGR S.p.A. bought a new stake in DexCom during the 4th quarter worth $3,231,000. Goodman Advisory Group LLC acquired a new position in DexCom in the 4th quarter worth about $1,293,000. Finally, Employees Retirement System of Texas acquired a new position in DexCom in the 4th quarter worth about $37,871,000. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently commented on DXCM shares. Mizuho raised their price objective on DexCom from $90.00 to $95.00 and gave the stock an “outperform” rating in a research note on Friday. Wall Street Zen lowered shares of DexCom from a “strong-buy” rating to a “buy” rating in a report on Sunday, May 10th. Royal Bank Of Canada raised their target price on shares of DexCom from $85.00 to $90.00 and gave the stock an “outperform” rating in a research note on Friday. Bank of America lowered their price target on shares of DexCom from $100.00 to $80.00 and set a “buy” rating on the stock in a report on Monday, May 18th. Finally, JPMorgan Chase & Co. upped their target price on shares of DexCom from $65.00 to $82.00 and gave the stock a “neutral” rating in a report on Friday. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $88.71.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.